Company intelligence / Profile preview

NephroGenex

Raleigh, North Carolina, United Statesnephrogenex.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 3

Overview

The company’s lead candidate Pyridorin® showed promise in Phase 2 for slowing progression of diabetic nephropathy and received FDA Fast Track designation. However, the pivotal Phase 3 trial failed to show significant benefit over placebo. As a result, programs were halted and assets were sold during bankruptcy proceedings.[1][3][6]

Therapeutic areas: Nephrology
Modalities: Small molecules (notably pyridoxamine dihydrochloride / Pyridorin)
Industry: Biotech

Drug pipeline

1 asset

pyridoxamine dihydrochloride

Phase 3

Indications: Diabetic nephropathy

Beyond the preview

Go deeper on NephroGenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NephroGenex.

Explore the full profile